Skip to main content
. 2011 May 11;31(19):7190–7198. doi: 10.1523/JNEUROSCI.1171-11.2011

Figure 5.

Figure 5.

A, Duration of ON-time in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA had no effect on the duration of ON-time (p > 0.05). B, Duration of ON-time with disabling dyskinesia in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA (3 and 10 mg/kg) significantly reduced the duration of ON-time with disabling dyskinesia when compared to l-DOPA vehicle (both p < 0.01). C, Duration of ON-time with nondisabling dyskinesia in marmosets treated with l-DOPA and R-MDMA (1, 3, or 10 mg/kg) or vehicle. R-MDMA (3 and 10 mg/kg) significantly increased the duration of ON-time with nondisabling dyskinesia when compared to l-DOPA vehicle (both p < 0.01). D, Duration of ON-time in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA (1 mg/kg) significantly increased duration of ON-time when compared to l-DOPA vehicle (p < 0.01). This extension of ON-time was not maintained when higher doses of S-MDMA (3 and 10 mg/kg) were administered (p < 0.01 when 1 mg/kg S-MDMA was compared to 3 mg/kg S-MDMA; p < 0.001 when 1 mg/kg S-MDMA was compared to 10 mg/kg S-MDMA). E, Duration of ON-time with disabling dyskinesia in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA had no significant effect on duration of ON-time with disabling dyskinesia (p > 0.05). F, Duration of ON-time with nondisabling dyskinesia in marmosets treated with l-DOPA and S-MDMA (1, 3, or 10 mg/kg) or vehicle. S-MDMA had no effect on duration of ON-time with nondisabling dyskinesia (p > 0.05). **p < 0.01 when compared to l-DOPA-vehicle; ††p < 0.01 when 1 mg/kg S-MDMA is compared to 3 mg/kg S-MDMA; ###p < 0.001 when 1 mg/kg S-MDMA is compared to 10 mg/kg S-MDMA. The values represent the mean ± SEM ON-time duration.